CTI BioPharma Reports Fourth Quarter and Full Year 2022 Financial Results ...Middle East

– Growing physician awareness and usage of VONJO® (pacritinib) drove quarterly double-digit revenue growth – – VONJO® net product revenue exceeded year-end goal with a total of $54 million for 2022 and $21.1 million in the fourth quarter, a 16% increase compared to the third quarter – –...

Hence then, the article about cti biopharma reports fourth quarter and full year 2022 financial results was published today ( Monday 06/03/2023 - 02:40 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( CTI BioPharma Reports Fourth Quarter and Full Year 2022 Financial Results )

Also on site :

• Disney and TikTok Shop Team Up To Bring Holiday Magic in First-Ever Super Brand Day
• Psychologists Say This Common 3-Word Phrase Can Accidentally Shut Down a Conversation (Hint: It’s Not ‘That Doesn’t Work’)
• Gloria Trevi Is HEAT Latin Music Awards’ Artista Oro, Celebrating ‘Everything She Has Achieved & Everything That’s Yet to Come’